Canada markets close in 3 hours 38 minutes
  • S&P/TSX

    -17.98 (-0.08%)
  • S&P 500

    -22.76 (-0.41%)
  • DOW

    -307.92 (-0.76%)

    -0.0012 (-0.16%)

    -1.47 (-1.77%)
  • Bitcoin CAD

    +3,733.30 (+4.28%)
  • CMC Crypto 200

    +36.63 (+2.75%)

    -50.80 (-2.07%)
  • RUSSELL 2000

    -8.26 (-0.38%)
  • 10-Yr Bond

    +0.0460 (+1.10%)

    -97.81 (-0.55%)

    +0.29 (+1.82%)
  • FTSE

    -49.17 (-0.60%)
  • NIKKEI 225

    -62.56 (-0.16%)

    -0.0002 (-0.03%)

Marvel Commences Final Study Required Prior to Initiating Human Trials

Calgary, Alberta--(Newsfile Corp. - March 21, 2023) - Marvel Biosciences Corp. (TSXV: MRVL) and its wholly owned subsidiary, Marvel Biotechnology Inc. (collectively the "Company" or "Marvel"), is pleased to announce that it has initiated the 4-week good laboratory practice (GLP) FDA investigational new drug (IND) enabling dose-ranging dog studies for its lead drug candidate MB-204.

"This dog study is the last of the two key primary animal studies we need to complete before entering phase 1 human clinical testing of our lead asset - MB-204," said Dr. Mark Williams, Chief Science Officer of Marvel Biosciences. "We are now planning our Phase 1 human trials, likely to be conducted in Australia upon the successful conclusion of this study and the previously commenced 4-week rat GLP study."

"We look forward to the completion of the rat and dog GLP studies of MB-204, and entering human trials, prior to the end of Q3 2023," said Rod Matheson, CEO of Marvel Biosciences. "We believe the profile of MB-204 is well-suited to address our primary markets, specifically depression and Alzheimer's disease. Owing to the immediate effect of the compound, we are confident that it will show the active effects early on in our clinical program."


In the United States, it is estimated that one in ten senior citizens over the age of 65 suffer from dementia. MB-204 is a novel solution to Alzheimer's that has similar properties to the Food and Drug Administration-approved drug, Istradefylline. MB-204 has, through the Company's studies, proven to be more effective and longer lasting than Istradefylline in pre-clinical studies.

MB-204 is a fluorinated derivative of the U.S. FDA-approved adenosine A2a receptor antagonist, Istradefylline. Both Istradefylline and MB-204 are highly active derivatives of caffeine, the most widely consumed psychoactive drug in the world. Caffeine consumption has been associated with a reduced risk of developing Parkinson's disease and Alzheimer's disease, as well as leading to an improved ability to concentrate.

About Marvel Biosciences Corp.

Marvel Biosciences Corp., and its wholly owned subsidiary, Marvel Biotechnology Inc., is a Calgary-based pre-clinical stage pharmaceutical development biotechnology company that utilizes a "drug redevelopment" approach to drug development. Historically, when a new class of drug is developed, it is optimized for a particular target, but typically only approved for a specific disease. Often, a new disease is identified which involves the same target, however, pending the remaining patent life, the originally approved drug may not have sufficient time left for it to be commercially viable to be developed for the new disease indication. Marvel develops new synthetic chemical derivatives of the original approved drug for the new disease indication. Patent protection is sought, as the new potential asset is developed by the Company. The Company believes the business model results in significantly less risk, cost and time to develop its assets compared to traditional biotechnology companies.

Marvel Biotechnology Inc. has currently developed several new chemical entities, using synthetic chemical derivatives of known, off-patent drugs, that inhibit the A2a adenosine receptor with application to neurological diseases (depression & anxiety, Alzheimer's, ADHD), and the non-neurological conditions of cancer and non-alcoholic steatohepatitis. Marvel is also exploring additional undisclosed targets to expand its asset pipeline.

Contact Information

Investor Relations:
Virtus Advisory Group
Tel: 416-644-5081

Marvel Biosciences Corp.
J. Roderick (Rod) Matheson, Chief Executive Officer or
Dr. Mark Williams, President and Chief Science Officer
Tel: 403 770 2469

Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSXV) accepts responsibility for the adequacy or accuracy of this press release.

All information contained in this news release with respect to the Company and its subsidiary, (collectively, the "Parties") were supplied by Marvel, respectively, for inclusion herein and each parties' directors and officers have relied on each other for any information concerning such Party.

This news release may contain forward-looking statements and other statements that are not historical facts. Forward-looking statements are often identified by terms such as "will", "may", "should", "anticipate", "expects" and similar expressions. All statements other than statements of historical fact, included in this release, including, without limitation, statements regarding the future plans and objectives of the Company are forward-looking statements that involve risks and uncertainties. There can be no assurance that such statements will prove to be accurate and actual results and future events could differ materially from those anticipated in such statements. Important factors that could cause actual results to differ materially from the expectations of the Company and include other risks detailed from time to time in the filings made by the Company under securities regulations.

The reader is cautioned that assumptions used in the preparation of any forward-looking information may prove to be incorrect. Events or circumstances may cause actual results to differ materially from those predicted, as a result of numerous known and unknown risks, uncertainties, and other factors, many of which are beyond the control of the Company. As a result, the Company cannot guarantee that the above events on the terms will occur and within the time disclosed herein or at all. The reader is cautioned not to place undue reliance on any forward-looking information. Such information, although considered reasonable by management at the time of preparation, may prove to be incorrect and actual results may differ materially from those anticipated. Forward-looking statements contained in this news release are expressly qualified by this cautionary statement. The forward-looking statements contained in this news release are made as of the date of this news release and the Company will update or revise publicly any of the included forward-looking statements as expressly required by Canadian securities law.

To view the source version of this press release, please visit